Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
Douglas G. Muse
Advertisement
Douglas G. Muse is consultant—Compendial Affairs, Eli Lilly & Co.
Articles by Douglas G. Muse
This article seeks to encourage continued dialogue among stakeholders to achieve consensus regarding excipient additives and processing aids.
Increasingly stringent audit requirements will make third-party accredited GMP audits critical for pharmaceutical excipients and raw materials.
Advertisement
Latest Updated Articles
Understanding Concomitant Components in Pharmaceutical ExcipientsPublished: February 3rd 2021 | Updated:
Third-Party Audits: Ensuring That Excipients Meet cGMP RequirementsPublished: September 1st 2018 | Updated:
Additives and Processing Aids in Pharmaceutical ExcipientsPublished: October 1st 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI and Accelerated Computing Propel the Biopharma Ecosystem Forward
2
Takeda Talks at CPHI Frankfurt 2025 About Smart Pharma Packaging Impacts
3
Thermo Fisher Launches OpenAI Partnership at CPHI Frankfurt 2025: Part One
4
Sustainability and Stability in Excipients
5
